Drugs / C9/CD5CAR/IL-15 NK cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07137481 | Feb 2027 → Jul 2030 expected | hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C9/CD5CAR/IL-15 NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07137481 ↗ |
| Modality | Cell therapy | “CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells” NCT07137481 ↗ |
| Route | Intravenous | “Given PO or IV” NCT07137481 ↗ |
| Route | Oral | “Given PO or IV” NCT07137481 ↗ |